Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 16;10(10):CD015930.
doi: 10.1002/14651858.CD015930.

Alpha 1 antitrypsin augmentation for alpha 1 antitrypsin deficiency associated lung disease

Patrick Glaister  1 , Nichola Hindle Robinson  1 , Amy Ward  1 , Chloe Bentham  2 , Iain Crossingham  2
Affiliations

Alpha 1 antitrypsin augmentation for alpha 1 antitrypsin deficiency associated lung disease

Patrick Glaister et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of alpha 1 antitrypsin augmentation therapy on respiratory disease in people with alpha 1 antitrypsin deficiency.

PubMed Disclaimer

Conflict of interest statement

CB declared that she has no conflicts of interest. She is a health professional working in a clinically relevant speciality (respiratory medicine).

IRC declared that he has no conflicts of interest. He is a health professional working in a clinically relevant speciality (respiratory medicine). He also acts as a Sign‐off Editor for Cochrane, but had no involvement in the editorial process for this protocol.

PG declared that he has no conflicts of interest. He works as an Evidence librarian within an NHS trust.

NHR declared that she has no conflicts of interest. She works as an Evidence librarian within an NHS trust.

AW declared that she has no conflicts of interest. She works as an Evidence librarian within an NHS trust.

References

Additional references

Anthonisen 1987
    1. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 1987;106(2):196-204. [DOI: 10.7326/0003-4819-106-2-196] [PMID: ] - DOI - PubMed
de Serres 2002
    1. Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002;122(5):1818-29. [DOI: 10.1378/chest.122.5.1818] [PMID: ] - DOI - PubMed
DeMeo 2004
    1. DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59(3):259-64. [DOI: 10.1136/thx.2003.006502] [PMID: ] - DOI - PMC - PubMed
Eldridge 2021
    1. Eldridge S, Campbell MK, Campbell MJ, Drahota AK, Giraudeau B, Reeves BC, Siegfried N, Higgins JPT. Revised Cochrane risk of bias tool for randomized trials (RoB 2). Additional considerations for cluster-randomized trials (RoB 2 CRT). https://www.riskofbias.info/welcome/rob-2-0-tool/rob-2-for-cluster-rando... 2021.
FDA 2023
    1. US Food and Drug Administration (FDA). What is a serious adverse event. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-a... 18 May 2023.
GOLD 2023
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2... 17 February 2023.
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2024. Available at gradepro.org.
Gøtzsche 2016
    1. Gøtzsche PC, Johansen H. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No: CD007851. [DOI: 10.1002/14651858.CD007851.pub3] - DOI - PMC - PubMed
Higgins 2024
    1. Higgins JPT, Li T, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Miravitlles 2017
    1. Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha-1 antitrypsin deficiency. European Respiratory Journal 2017;50(5):1700610. [DOI: 10.1183/13993003.00610-2017] - DOI - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] - DOI - PMC - PubMed
Monk 2013
    1. Monk R, Graves M, Williams P, Strange C. Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. COPD 2013;10(4):411-5. [DOI: 10.3109/15412555.2012.758698] [PMID: ] - DOI - PubMed
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 8.5.1. The Cochrane Collaboration, 2024. Available at revman.cochrane.org.
Sterne 2019
    1. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. - PubMed
Stoller 2012
    1. Stoller JK, Aboussouan LS. A review of alpha 1-antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine 2012;185(3):246-59. [DOI: 10.1164/rccm.201108-1428CI] [PMID: ] - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources